Glenmark Pharmaceuticals seeks licensing deal for ISB 2001 drug candidate, plans growth with semaglutide in India.

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some ...

Globalpharma, which is a wholly owned subsidiary of Dubai Investments, is laying the groundwork to manufacture generic versions of blockbuster drugs such as Ozempic, positioning itself ahead of ...

The company is preparing a Phase 3 trial of enobosarm with a novel formulation that could extend its patent life.

Novo Nordisk continues to deliver strong revenue, profit growth, and high economic profitability. Read why I rate NVO stock a ...

At CTO West Coast an expert from Genentech outlined the company’s net zero goals, efforts, challenges and initiatives ...

In an effort to promote the use of genuine products, Novo Nordisk is offering a one-time first-month offer for Wegovy at $199 ...

Thammasat University Hospital, in collaboration with Novo Nordisk Pharma (Thailand) Ltd. (“Novo Nordisk”), announced a ...

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...

Eli Lilly (NYSE:LLY) focuses on researching, developing, and bringing to market a wide range of medicines, including ...